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ABSTRACT

Since 2010 the Center for Disease Control (CDC) and its Advisory Committee on
Immunization Practices (ACIP) have recommended annual influenza vaccinations for all
persons aged six months and up (ACIP, 2017). In December of the same year, the
Agency of Health and Human Services (AHHS) unveiled Healthy People 2020, a series
of health indicators and corresponding 10-year objectives. This newest iteration of the
Healthy People program set target influenza vaccination levels for healthy adults 18 and
older at 80% (AHHS, 2010).
Aside from the inherent health benefits, multiple studies conducted over the past
decade suggest there may be significant economic benefits to a highly-vaccinated
population. Depending on the effectiveness of seasonal vaccines, the cost of vaccinating a
U.S. adult can be outweighed by the health care savings from the resulting reduction in
direct and indirect infection treatment costs.
As the state of Vermont considers including influenza vaccinations in its statemandated Vermont Vaccine Purchasing Program (VVPP), it presents a unique
opportunity to conduct a state-wide case study on the potential cost-saving implications
of a universally available influenza vaccination.
This study takes a historical perspective and looks back at Vermont’s influenza
cost, usage, and treatment information since the vaccine was recommended in 2010.
Using data generated from Vermont’s immunization registry, de-identified claims data,
CDC-reported statistics, and numerous published economic studies, this research answers
the question: “What societal costs/savings would have been witnessed if the influenza
vaccine was included in the VVPP since 2010?” and, more important, what policy
changes can be made now to realize savings in the future?
Using a dynamic transmission model embedded in cost-benefit analysis, this
research concludes that influenza-related savings of 6.2% would have been experienced
over the five flu seasons between fall 2010 and summer 2015. Most of the savings are
generated by the increased vaccination rate associated with a universal vaccination
program. Creation of such a program in the state of Vermont would likely be
economically beneficial.
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INTRODUCTION
Between 5% and 25% of the global population can become infected with the
influenza virus in any given year. Annually, hundreds of thousands are hospitalized by
the pathogen; tens of thousands die. The morbidity and mortality associated with
influenza can be mitigated by vaccination. Since 2010 the CDC has recommended all
individuals aged 6 months and older receive an annual flu vaccine. Historically, the
vaccine has been suggested for only populations at high risk of complication or
transmission – children, the elderly, and healthcare workers. Only recently have working
adults been recognized as vectors of the disease, acting as a bridge between other age
groups. Only about 40% of working-age adults receive a flu vaccination each year.
This thesis will assess the costs and benefits of a universal vaccination program in
the state of Vermont. An economic analysis of an epidemiological intervention is
necessarily multidisciplinary. This paper includes considerations of economics and
epidemiology in both its literature review and methods. It also includes information on
the virus, its vaccine, and the public health mechanisms through which a universal
vaccination program would be implemented.
This study is multidisciplinary in its nature, drawing on concepts from
epidemiology, economics, and statistics. The literature review in this thesis will cover
influenza, vaccinations, epidemiological models, economic models, existing universal
vaccination programs, historic trends, and an overview of the data sources used.
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The model itself is unique. Typically, vaccine program cost-benefit analysis and
cost-effectiveness analysis measure the costs of vaccination against the cost of treatment.
In the case of this research, I compare the total historic societal cost of influenza
vaccination and treatment to what that cost would have been if there was a universal
vaccination program. This model improves upon prior research by embedding a dynamic
transmission model within a 5-year cost-benefit model covering the entire state of
Vermont. The distinct combination of scale, time, and epidemiological factors accounts
for the variable nuances of influenza vaccination in a way previous research has not. The
methods section of this thesis includes details on the transmission model used,
information on how the historic variables were collected, and how those variables were
adjusted for inclusion in the intervention – a universal influenza vaccination program.
Finally, this paper discusses the results and limitations of the model, as well as a
discussion section which addresses the implications of the findings. In the end, this
research concludes that increased vaccination rates among adults aged 18-64 is
economically beneficial, and recommends that a universal influenza program be
implemented in Vermont and supported by the state-mandated Vaccine Purchasing
Program.
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CHAPTER 1: LITERATURE REVIEW
The research, analysis, and discussion included in this paper draw from a wide
range of socioeconomic models and literature. The focal point of this project is an
epidemiological model embedded within a cost analysis model – which is contextualized
by the State of Vermont’s public health climate. The literature reviewed must then
support each of these components and included information on influenza, vaccinations,
public health, economics, and infectious disease modeling.

1.1. Influenza
The influenza virus is a consistent, annual, and mitigatable public health risk that
affects large portions of the U.S. population every year. This research deals only with
inter-pandemic, or “seasonal” influenza. Seasonal influenza epidemics typically peak in
the late fall through early spring and affect individuals across all demographics (ACIP,
2011; Lagacé-Wiens, 2010). Influenza epidemics vary widely in severity. The true
number of infected individuals is difficult to know. The range of infected individuals has
been identified as 1% to 26% (Bridges, 2000) and 5% to 20% (Kryscio, 2010). On
average, influenza results in 36,000 deaths per year, with an additional 200,000
hospitalizations (Maciosek, 2006; Kryscio 2010). Death and serious illness is most
common among children, the elderly, and pregnant women. The increase in mortality is
largely due to pneumonia and influenza, but additional deaths are caused by exacerbated
chronic illnesses in the respiratory and circulatory systems (Cox, 2000). Since 2010, the
CDC’s Advisory Committee on Immunization Practices has recommended “routine
3

annual influenza vaccination for all persons aged ≥6 months who do not have
contraindications” (ACIP, 2017, p.2).
Influenza refers to a group of three segmented RNA genome viruses called
orthomyxoviruses. The virus has threatened populations for thousands of years with
possible pandemics occurring in ancient history – Hippocrates wrote about the spread of
illnesses as early as 412 B.C. In 1891, the germ associated with influenza was named
Bacillus influenzae by Pfeiffer, but the flu was recognized as a pathogen a year earlier. In
1933, Wilson Smith, Christopher Andrews, and Patrick Laidlow at the National Institute
of Medicine “discovered” influenza as a virus during research on the pathogen’s
development. Soon after, in 1936 the first influenza vaccinations were created from
inactivated viruses replicated in mice cells and then in the embryo of a hen (Kuszewski,
2000).
The viruses are typically identified as A, B, and C (Lagacé-Wiens, 2010; Cox,
2000). Of these three viruses, A and B are associated with seasonal morbidity, mortality
and economic losses (Cox, 2000). Influenza A and B viruses were first isolated in 1933
and 1940, respectively. Influenza A is responsible for the majority of seasonal flu
outbreaks and all epidemics (Lagacé-Wiens, 2010). The A virus is often sub-typed
according to the arrangement of its surface glycoproteins. One of fifteen different
hemagglutinin (HA) and one of nine different neuraminidase (NA) are arranged to give a
unique identifier to the various viruses. While all the possible combinations of these
glycoproteins have been found in avian hosts, only H1N1, H2N2, and H3N2 have been
associated with significant epidemics in humans.
4

Outbreaks of Influenza A occur when the virus’ genes mutate, changing its
properties and exposing a population to a varied version of the virus. These mutations can
occur in two ways, colloquially referred to as antigenic shift and antigenic drift.
Antigenic shift occurs when a distinct HA emerges, changing the glycoprotein
composition, sometimes resulting in a pandemic. Antigenic drift refers to more subtle
variations in the virus’ structure, but still can cause a partial loss of immunity in a
population. Antigenic drift is responsible for seasonal epidemics or inter-pandemic
influenza. Influenza B can also mutate, but slowly, in a way like antigenic drift
(Kuszewski, 2000; Lagacé-Wiens, 2010; Lahariya, 2016).
Some influenza endemics begin in avian species. The virus reproduces in the
gastrointestinal system of waterfowl and shore birds – which acts as a “reservoir” - where
the virus is asymptomatic. It is excreted from the birds into bodies of water where it can
infect larger birds and mammals – including humans, horses, seals, whales, and pigs.
Endemics can also begin in swine – although human to human transmission of swine flu
is extremely rare (Cox, 2000). Transmission between humans occurs primarily through
large-droplet aerosols associated with sneezing or coughing, although formites also
contribute to the spread of the virus. Once contracted, the virus grows in the trachea and
bronchi, where it can spread to infect other individuals (LaForce, 1994).
The reason for the seasonality of the influenza virus remains unknown.
Researchers speculate it is associated with crowding during the cold winter months. This
belief is corroborated by the increased spread of influenza in schools, dorms, and military
compounds. The sterilizing properties of ultraviolet light might also reduce transmission
5

from formites during warmer months (Lagacé-Wiens, 2010). Seasonal influenza
epidemics begin and escalate quickly, typically peaking within two to three weeks and
lasting for five to ten weeks. The virus follows a fairly predictable course – first infecting
school children before spreading to their parents and guardians before finally reaching the
elderly (Lagacé-Wiens, 2010).
This pattern has been known for decades. In a 1982 paper about the morbidity and
mortality of influenza in Huston Texas form 1974-1981, W. Paul Glezen documents a
reoccurring “age shift” that occurs each influenza season – the age of the individuals
seeking medical care due to infection increases as the season progresses. Glezen writes,
“during the early stages of the epidcmics, a disproportionate number of cases have been
older school-aged children in the 10-to-19-year age range” (Glezen, 1982 p.29). In fact,
more than half (53.5%) of the documented infections in the early stages of the epidemic
were found in school-aged children. During the late stages of the epidemic, children
made up just over a third (35.2%) of all flu-related medical visits. School attendance
appears to be one of the driving factors in this trend. The data collected through the 1982
research found that during two of the flu seasons included in the study the virus began to
spread most rapidly in early December, but infection transfers slowed later in the winter.
Glezen concluded that “that school holidays interrupted and probably dampened the
effect of these epidemics on the community” (Glezen, 1982 p.29).
The predictable path of the spread of influenza highlights another important
concept in epidemiology – that of selective vaccinations. It is more beneficial to
vaccinate some individuals than others, and absent a universal vaccination program,
6

understanding the movement of an infection through a community is paramount to
mitigating the economic and medical effects it can have on a population. Epidemiology –
the study of the transfer of infectious diseases – helps develop an understanding of who
to vaccinate and when to vaccinate them.

1.2. Vaccinations & Epidemiology
Epidemiology studies the spread and control of infectious diseases. It is vitally
important to consider epidemiological factors in all research involving contagions,
including economic research. Vaccination in particular is one of the most cost-effective
interventions that can be implemented among a population (Lahariya, 2016).
Vaccinations have been gaining recognition over the past few decades for their
importance in controlling disease spread and achieving various public health outcomes.
“Vaccine epidemiology,” as Chandrakant Lahariya calls it, “could be described as an
interface between public health, basic medical sciences, and clinical medicine aimed at
maximizing the benefit of existing knowledge in these areas” (Lahariya, 2016, p.2).
Economic evaluations in healthcare often omit epidemiological practices and principles
which results in inaccurate modeling. Cost-benefit analysis of the influenza vaccination
requires an understand of vaccine epidemiology to properly model any scenarios.
A vaccine is typically a lab-made version of the pathogen that can be
administered to a host in order to initiate the appropriate immune system response before
the pathogen is naturally encountered. The vaccine pathogen or antigen can be
inactivated, attenuated, or a lab-created biological substance (Lahariya, 2016). Influenza
7

vaccinations work by introducing the body to a mutated version of the influenza virus
before the host is otherwise introduced to the virus. When successful, the body is able to
build the necessary antibodies to protect against natural infection. Despite significant
advances in medicine since the creation of the vaccine, the vast majority of it is still
produced in chicken eggs and supplied at a rate insufficient to keep up with global
demand. Influenza vaccines are typically made to protect against three of the viruses,
H1N1, H3N2, and B, although a four-virus variation is in circulation. The success of the
vaccine is dependent on the accuracy of the vaccine to the antigens mutated genetic
composition. The proximity can vary widely between years, which complicates modeling
(Lagacé-Wiens, 2010; Cox, 2000). There is, however, a loose pattern of variation. Cox
and Subbarao (2000) write: “each successive antigen variant replaces its predecessor such
that the co-circulation of distinct antigenic variants of a given subtype occurs for
relatively short periods. During the past decade, new epidemic variations of influenza
often are first detected in China before they spread to other locations” (p.411).
Influenza vaccinations reduce infections in a population in three ways. Primarily,
they reduce the likelihood of infection in the patient. This additional reduction in the
chance of infection is called vaccine effectiveness (VE) and is dependent upon the
accuracy of the vaccine compared to the seasonal viral strain and varies widely from
year-to-year (Ohmit, 2008). Vaccine effectiveness is also dependent on the cohort
receiving the vaccination. For example, the same vaccine often has a lower VE in older
populations than it does in children and working-aged adults (Kim, 2014). Vaccine
effectiveness and vaccine efficacy are sometimes used interchangeably, but they refer to
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different concepts. Vaccine effectiveness represents the added resistance to the individual
receiving the vaccine; vaccine efficacy is the increased resistance of the population, and
sometimes called “program effectiveness” (Lahariya, 2016; Shim, 2012). This research
uses VE to represent only vaccine effectiveness – the individual component. The second
public health benefit is the “herd” – the reduced likelihood of infection in the
unvaccinated population. This effect exists because as vaccination reduces the likelihood
of infection in the vaccinated population, it also decreases the total number of infected
individuals in a population who are then capable of further infecting the unvaccinated
population. Some research has suggested that this indirect effect of vaccinations is greater
than the direct effect on the vaccinated population (Pradas-Velasco, 2008). The herd
effect and herd immunity are related, but not the same measure. The herd effect is name
for the indirect effects of vaccination while herd immunity typically refers to a state in
which a group achieves emergent resistance by having a higher vaccination rate than the
“herd immunity threshold” (H). The herd immunity threshold is the minimum portion of
a population that must be immunized for the entire population to be resistant (Lahariya,
2016). Finally, vaccination has a residual effect that is not realized until future influenza
seasons – research shows that previous natural infection and previous vaccination reduce
the susceptibility of a population to future infection (Lagacé-Wiens, 2010). Research
shows that the herd immunity threshold in the United States is about 80% of the
population (Plans-Rubio, 2012).
The speed at which the virus spreads can be evaluated through several different
measures, but this research uses exclusively reproductive rate. The natural reproduction
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rate, or R0, is a measure of secondary infections expected to result from each case of
influenza, absent an intervention. R0 less than 1, for example, indicates an infection is in
decline – each person who contracts the virus will pass it on to fewer than one other
person, and an epidemic is impossible (Fine, 2011).
R0 = 1

Each case will generate one new case

R0 > 1

An infectious disease, with exponential growth

R0 < 1

A pathogen in decline, each case will produce fewer new cases (Laharya, 2016)

Vaccinations work to reduce the attack rate of a virus by lowering both the
infected population and susceptible population. By vaccinating individuals, they are less
likely to be at risk of contracting the infection from others, and therefore less likely to
pass an infection to others who remain at risk. Reducing the attack rate from R0 (the rate
of spread absent any intervention) to R1 (the rate of spread with intervention) is
dependent on two variables – the success of the vaccination and the adoption of the
intervention. The reproductive rate of a pathogen is difficult to measure, and is dependent
on various factors such as the means of transmission and the contagious period of the
host. The R0 of influenza is typically estimated to be 1.3, but varies depending on the
year (Coburn, 2009).
Some groups are more advantageous to vaccinate than others. Before 2010, for
example, the CDC did not recommend vaccinating working-aged adults (ACIP, 2018).
As mentioned earlier, selective vaccination of groups can be a highly cost-effective way
to reduce incidence among at-risk groups with indirect benefits to the population. For
example, the vaccination of healthcare workers can help reduce the circulation of the
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influenza virus among healthcare workers. Vaccinating clinicians has been shown to
reduce influenza-related hospital admissions by 32-39% and reduced pneumonia and
influenza related hospital deaths by 43-65% among patients over 45 years of age (Kim,
2014). Vaccinations of school children are also important and have been shown to slow
the spread of disease. In Japan in the 1990s it was shown to reduce morbidity and
mortality in the elderly (Fine, 2011). Other studies have corroborated this relationship.
Vaccinations administered to elderly populations have a lower VE than those given to the
rest of the population, a fact that is troubling given the fact that the elderly have high
influenza-associated morbidity rates. In fact, a 20 year-long program intended to protect
this high-risk group was successful in reducing morbidity in the United States. As it turns
out, the best way to protect the elderly from influenza is to vaccinate the people who
would transfer it to them – healthcare workers and family members. This suggests that
seniors benefit more from the indirect and herd effects of vaccination than they do from
receiving the vaccination themselves (Kim, 2014).
In 2009, Jan Medlock and Alison P. Galvin published Optimizing Influenza
Vaccine Distribution, in which they developed an age-structured transmission model that
tracked 17 age cohorts to evaluate the mixing of peoples and the corresponding spread of
disease. The research found that it is most cost effective to vaccinate children and adults
aged 30-39. This is because schoolchildren account for a disproportionate amount of
disease transmissions and their parents act as “bridges” to the rest of the population.
Medlock and Galvin believe their findings are important for determining selective
vaccination distribution in a supply-constrained scenario (Medlock, 2009).
11

Absent the supply constraint, however, public health programs should attempt to
vaccinate at least 80% of the entirety of their population and 90% of high-risk individuals
according to Healthy People 2020 and Healthy Vermonters 2020. The actual herd
immunity threshold varies by year and cannot be predicted. A 2012 paper by Pedro
Plans-Rubio calculated the herd immunity threshold for five different flu seasons using
R0, vaccine effectiveness, and vaccine coverage. He concluded that in some years, as
little at 30% to 40% coverage is necessary in a population to prevent a seasonal epidemic,
but the herd immunity threshold can approach 100% in others. He concluded that the
vaccination goals set forth by the United States in 2010 (80% of working-aged adults)
were adequate to result in herd immunity in most years, and a substantial herd effect in
others (Plans-Rubio, 2012). This research does not use a herd immunity threshold but
does consider the herd effect by using a dynamic transition model to capture the indirect
benefits associated with vaccination – i.e. the reduction on illness in the unvaccinated
population.

1.3. Infectious Disease Transmission Modeling
Infectious disease modeling attempts forecast epidemiological events or test
hypotheses and document mathematical patterns of disease as they spread through a
population. Dietz and Schenzle (1985) summarize the practice eloquently:
The focus of concern of infectious disease modeling is the transmission of the
disease agents through the population. A detailed model would describe at any time
the number of [viruses] in each member of the host population.… The transmission
model has to include always two basic components: (a) the course of an infection
within one individual once the [viruses] have entered, (b) the mode of spread of
[viruses] between individuals (p.169).
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Biology typically deals with the first of these components while epidemiology –
by necessity – concerns itself with both. In the case of influenza, the course of infection
is important to an understanding of how long an individual is contagious, while the mode
of spread helps determine the rate of transmission (and therefore the R0 or attack rate).
These transmission models can be divided into two categories – static and
dynamic. Static models “implicitly assume that the probability of disease exposure is
unaffected by an intervention against it, and therefore the probability of exposure to the
disease does not change over time,” and they typically underestimate the effect of
vaccination (Lugnér, 2010 p.44; Bauch, 2009; Van Vlaenderene, 2013). Cost-benefit
analysis must therefore utilize dynamic models, which incorporate the compounding
effects of vaccination over time. (Lugnér, 2010; Pradas-Velasco, 2008).
There have been attempts at approximating dynamic and herd effect modeling in
static models, but they are a poor replacement for true dynamic models. In 2019, Chris T.
Bauch et al. published a paper in which they compared outcomes of a pseudo-dynamic
cohort model to those of a dynamic compartmental transmission model. They found that
their best efforts approximated the outcomes of an epidemiological model, but only if the
reproductive number of the virus was exceedingly high. Any lower than that, or with a
small population, and the pseudo-dynamic model fell short of the accuracy of a dynamic
model. Bauch et al. tested a susceptible-exposed-infected-recovered (SERI) dynamic
model, which is very similar to the susceptible-infected-recovered model used in this
research. (Bauch, 2009). In 2013, Van Vlaenderen and others published An
Approximation of Herd Effect Due to Vaccinating Children Against Seasonal Influenza –
13

a Potential Solution to the Incorporation of Indirect Effects Into Static Models. As with
Bauch, Van Vlaenderen’s attempts at simplifying the modeling of infectious diseases was
only partially successful. The paper compared two previously published linear
approximations of disease transmission models (including Bauch’s study) but concluded
that “a non-dynamic approximation such as those presented here cannot replace a fully
dynamic modelling approach and should only be intended for a preliminary assessment of
the herd effect” (Van Vladerene, 2013 p.11).
Dynamic transmission modeling is utilized by a minority of economic studies. In
fact, between the years of 1976 and 2005, 72% of vaccine cost-benefit analysis did not
consider the herd effects of immunization programs. Nymark et al. published a systematic
review of methods used in economic evaluations of vaccination programs, assessing 172
English-language publications written over 40 years. They concluded that “only 28% of
the cost-effectiveness analyses of vaccines in this review included herd immunity effects.
55% used static models, which cannot accurately predict herd immunity,” and “there are
no recommended methods available for incorporating herd immunity using a static model
and the reliability of these results is questionable” (Nymark, 2017, p.6837). Failure to
incorporate dynamic modeling into economic models not only misstates the effects of
vaccination programs, it limits the discussions and strategies that can be employed by
public health professionals by omitting time as a variable (Lugnér, 2010).
A commonly used dynamic transmission model is the susceptible-infectedresistant (SIR) model. This compartmental epidemiological model is used in this research
and is described in detail in the methods section. The epidemiological work in this
14

research is based on the mathematical modeling found in Pradas-Velasco’s 2008 paper,
Dynamic Modelling of Infectious Diseases.

1.4. Cost-Benefit Models
There have been numerous economic appraisals of vaccination programs written
over the past 40 years, and each year, the number of new publications increase
exponentially (Nymark, 2017). Unfortunately, few of these models incorporate the
multidisciplinary approach necessary to truly evaluate the nuances of a vaccination
program. Papers written by economists often fail to capture the dynamics of
communicable diseases and opt instead to conduct cost-benefit analysis using static
models absent epidemiological variables. Conversely, papers written by medical
professionals often fail to incorporate the various direct and indirect costs associated with
influenza – often omitting variables such as lost productivity. Furthermore, the papers
often have too short a time-horizon: even though most of these papers mention the wide
variation in influenza illness distribution by year, few of the articles include more than
one or two years in their analysis. Each of these papers compare the cost of vaccination to
the cost of treatment. Some are cost-benefit analyses; some are cost-effectiveness
analyses. Although the model included in this paper draws heavily from each of these
publications, a new model is needed to compare the total societal cost of influenza before
and after an intervention. The model must include a larger time horizon, all societal costs,
and a dynamic disease transmission component.
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This summary of cost-analysis literature was conducted by evaluating two
published systematic reviews: Ting et al. and Nymark et al., both published in 2017. Ting
et al. provided a review of cost-effectiveness research while Nymark et al. reviewed
methods used to calculate herd immunity. Only papers that used cost-effectiveness
analysis, cost-benefit analysis, or dynamic infectious disease modeling were included in
this literature review. Additional sources were included whenever they were heavily cited
in the papers found through the two systematic reviews.
In March 2017, Ting, Sander & Ungar published Systematic review of the costeffectiveness of influenza immunization. The authors used a systematic literature search
to identify 31 studies published between 1996 and 2014. A database search produced
4,221 individual economic publications. Title and abstract screening reduced this
number to 41 studies that evaluated entire populations or sub-groups for any
immunization vaccination formulation. Applying quality appraisal further reduced this
number to just 31 publications. Twenty-one of these studies were conducted on healthy,
working-aged adults. These publications, in addition to literature on Vermont’s
population and health costs and epidemiological SIR models, and other cost-benefit
research are the foundation of this study.
In general, the studies sought two different results. Studies that sought to
calculate the cost of a quality adjusted life year (QALY) are of less value to this research
(Maciosek et al., 2006; Sander et al., 2010). While they provide useful information on
various cohorts, they do not utilize the framework which will be implemented here.
QALYs are a useful tool, but the goal of this paper is to compare the societal costs of two
16

methods of vaccine distribution, and not calculate the cost of added years of life. The
other studies calculated “breakeven” points: dollar values which the cost of administering
the vaccination would need to be below to economically justify a universal vaccination.
This research draws more from the latter of these study types to construct the
cost-benefit model. Similar to the breakeven models, both indirect and direct costs will
be included in the analysis. However, a key difference is how the costs will be compared.
In the breakeven models, the average societal cost of vaccination is compared against the
societal cost of illness. In the case of this research, the cost of vaccination (VCost0) and
illness (TCost0) will be summed together and compared to the cost of vaccination
(VCost1) and illness (TCost1) after an intervention, to determine the cost effectiveness of
the intervention.
The first placebo-controlled cost-effectiveness study of influenza vaccines was
published in 1995 by Kristen L. Nichol et al., but it was not included in the Ting review
because it fell outside the timeframe. Although the associated costs and benefits have
evolved over the past 20-plus years since its publication, Nichol et al. create a framework
which has become the basis for many of the studies included in this literature review.
This research studied 849 subjects between the ages of 18 and 64. Half of the subjects
were given a placebo; half were given the flu vaccine. The research used US dollars to
calculate costs/savings and included the cost of vaccination, medical care for side effects,
and medical care avoided due to vaccination for direct costs. Indirect costs included
work time lost due to vaccination, illness, and side effects. This research calculated a cost
savings of $46.85 in 1995 USD per person vaccinated and concluded that “vaccination
17

against influenza has substantial health-related and economic benefits for healthy,
working adults” (Nichol, 1995, p.891).
The first breakeven study was published in 2000 by Carolyn Buxton Bridges et al.
The authors note that while the benefits of vaccination for individuals over 64 years old is
well documented, there is a lack of studies evaluating 18-to-64-year-olds. The researchers
conducted a randomized, double-blind trial with placebo controls over the course of two
flu seasons. The study calculated the cost of administering a vaccination as $24.70 per
person. This included the $10 vaccine (supplies + nurse’s time), and 30 minutes of lost
work time for the patient. The study then calculated the average influenza-like illness
(ILI) cost for each group and added it to the cost of the vaccination.
The results varied dramatically between the two years. This is because the
vaccination circulated in the first year of the study (1997-1998) was largely ineffective.
The ILI costs alone in the influenza group were almost twice as high as in the placebo
group. The total cost of year one was $124.21 per vaccinated person and $58.62 per
unvaccinated person.
In the second year of the study, the vaccination was more effective. Only 14% of
the vaccinated group became ill, compared to 21.5% of the placebo group. This resulted
in ILI costs of $26.73 in the vaccinated group and $40.26 in the control group. Still, after
adding the cost of vaccination, the total cost of the vaccinated group exceeded the
placebo group at $51.43 (Bridges, 2000). This study suggests that vaccinating healthy,
working-aged adults would not be cost-effective. However, the population of this study
was rather small – it looked only at employees of Ford Motor Co. in Dearborn, Michigan.
18

It also calculated the cost of vaccination for individuals with hourly salaries of $30, well
above Vermont’s average wage. Certain assumptions would need to be changed to make
these findings applicable to Vermont. More importantly, this study did not consider the
indirect effect of vaccination – herd immunity. Throughout the literature, and within this
study itself, it is evident that the marginal cost of vaccinating an individual is less than
the benefits associated of lowering their chance of infection.
In 2001 Kristin L. Nichol published Cost-Benefit Analysis of a Strategy to
Vaccinate Healthy Working Adults Against Influenza. It is the second of three papers
written by Nichol that are included in this literature review, and a foundational piece of
research for the cost-benefit modeling for Vermont’s population. Here, Nichol takes the
societal perspective, and incorporates all costs both direct and indirect. Nichol’s basic
cost model is as follows:
Net Costs (Savings) = Cost of Vaccination – Costs Averted Due to Vaccination

The variables used include illness rate, the percent of cases medically attended, work
absenteeism, hospitalization rates, dosage prices, Medicare reimbursement rates, health
care provider visits, medications, and the hourly wage of patients. Nichol also considered
the cost of the side-effects associated with the vaccination: although there was a slight
increase in reported side-effects from a vaccinated cohort (when compared to a placebo
group), Nichol writes that “the most likely estimate for work absenteeism and health care
provider visits due to side effects from vaccination [itself] is close to 0” (Nichol, 2001
p.751). Neither Nichol’s 2001 paper nor this research include a willingness-to-pay
variable for avoiding side effects.
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Nichol calculated the potential for societal savings using Monte Carlo simulation,
and concluded that the “mean cost per person vaccinated… resulted in net savings of
$13.66 for each person vaccinated” (p.753). The results varied from savings of $174.32
per person to a cost of $21.27 per person. Overall, however, the model showed that
vaccination resulted in net savings 95% of the time (Nichol, 2001). Nichol’s research
was most sensitive to the illness rate and the lost productivity of the population. The
research did not use a dynamic epidemiological model to capture the herd effect of
increased vaccination rates – it only evaluated the cost of vaccinating individuals against
the associated healthcare savings. If Nichol truly wanted to take a societal perspective,
her model should have included more epidemiological factors.
A year later, Patrick Lee et al. published Economic Analysis of Influenza
Caccination and Antiviral Treatment for Healthy Working Adults (2002). This piece of
research reviewed previously published data to calculate the net benefit of influenza
vaccination from a societal perspective. Healthy, working adults aged 18 to 50 were
included in the study. The net benefit of the various treatments examined was simply
calculated as:
Net benefit (cost) = benefits of vaccination and treatment – cost of vaccination and treatment

The research used a static decision-tree model to evaluate the costs of various
vaccination and treatment paths and took a societal perspective, accounting for direct and
indirect costs and benefits. Lee et al. assigned various probabilities and costs to each
branch of the decision tree and altered those probabilities to assess the cost-effectiveness
of various scenarios. The economic benefits are only visible when epidemiological
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factors are considered (Valenderene, 2013). Instead, Lee et al. used a linear model that
did not account for the increasing marginal benefits of additional vaccination – the herd
effect. Lee et al. also used an unusually high value for lost productivity – 2.8 days. This
number may have offset the reduced savings associated with static models. The authors
note that they assumed “return to normal activity” as a return to work.
Lee et al. concluded that vaccination provided a net benefit to society both when
paired with antiviral treatment and alone. Vaccination alone provided a net benefit of
$29.50 per person vaccinated. The researchers compared their results to those of Nichol
et al. and contrasted their work to that of Bridges for two reasons. First, Bridges et al.
did not consider the costs/benefits of side effects from influenza medications. Lee et al.
evaluated these using a willingness-to-pay survey and included it in their calculation.
Second and more important, Bridges et al. calculated the lost productivity at 0.5
workdays per episode. The Lee et al. research states that if they had used 0.5 days per
episode instead of 2.8 (a number previously published in two studies) the resulting
analysis would not have been cost-effective. (Keech, 1998; Schoenbaum, 1987).
The most contemporary study addressed in the Ting, Sander & Ungar systematic
review was written by Nichol, Mallon, and Mendelma. Cost Benefit of Influenza
Vaccination in Healthy, Working Adults: An Economic Analysis Based on the Results of a
Clinical Trial of Trivalent Live Attenuated Influenza Virus Vaccine was published in
2003, and is somewhat divergent from the prior studies in both subject and methods.
First, this piece of research focuses only on vaccination by live attenuated influenza virus
vaccine (LAIV) – a nasal spray. Second, although the study conducted a placebo21

controlled blind study to calculate decreased health care utilization and workplace
absenteeism, the study relies more heavily on alternative sources to produce some of its
estimates. Third, this study included a calculation of “reduced effectiveness” to account
for the reduced productivity of employees who work through their illness. The study also
calculated a “breakeven cost” rather than a savings/loss per person.
A 2005 cost-effectiveness study conducted by Michael B. Rothberg and David N.
Rose concluded that the vaccination of health working-aged adults was “reasonable
economically, and in certain circumstances is cost saving” (Rotherberg, 2005 p.68). The
analysis used ten years of surveillance data from the World Health Organization and
measured outcomes in illness days, costs, and QALYs. The research tested various
strategies including increased vaccination, treatment with amantadine therapy, and the
status quo over the course of the ten years. The researchers found that the most
economical public health strategy varied from year to year. This research did not evaluate
the herd effect of vaccination in any way.
Unfortunately, although much can be learned from each of these studies, none of
them are robust enough to fully capture the costs and associated benefits of a vaccination
program. Few of these studies were conducted over a long enough period to properly
account for the annual variations in proximity between vaccine and virus antigens. It is
possible for a vaccine to be highly cost-effective one year and ineffective the next. The
studies that were often cited used liberal figures for key variables such as reduction in
workforce productivity. By far the most persistent noteworthy omission from these
studies is consideration for the epidemiological factors of vaccination programs. This
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research intends to address these shortcomings in order to create a model that is societal
in measure, dynamic in nature, and more longitudinal in scale.

1.5. Regional Universal Influenza Vaccination Programs
Two communities in our region have already implemented universal influenza
vaccination programs: Ontario and Rhode Island. Rhode Island runs its program through
a vaccine purchasing program like the VVPP mechanism referenced in this research.
Unfortunately, little data has been made available.
Rhode Island includes all vaccinations recommended by ACIP in its adult
vaccination program – including influenza. The state administered over 450,000 doses of
the flu vaccine during the 2015-2016 season. As of 2016, vaccination rate growth has
been modest, increasing from 37.6% of 18-to-49-year-olds during the 2011-2012 season
to 45.4% during the 2015-2016 season. By 2015 the state saw an increase in vaccination
rates from 67% to 88.5% among healthcare workers, and claims that the inclusion of
influenza in their vaccine program eliminated a cost barrier and increased access in such
a way that racial and ethical disparities were reduced. Unfortunately, no further analysis
has been conducted by Rhode Island (RI, 2015).
Ontario, on the other hand, has had several journal articles published on the topic
of universal influenza vaccinations. Ontario introduced its “universal influenza
immunization program” (UIIP) in 2010 for all residents aged 6 months and older. The
program has been associated with higher vaccination rates in children and adults and a
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reduction in influenza associated mortality and health care usage. A 2010 paper by Beate
Sander et al. tested the cost-effectiveness of the program with multivariate regression
supported by sensitivity analysis. The research created a historical baseline for influenza
costs and medical visits and studied the effect of Ontario’s UUIP using nearby nonuniversal providences as a control group. The primary goal of this research was to
establish a cost per quality adjusted life year (QALY) gained through the UIIP. Although
QALYs are not of particular interest to this study, many of their other findings are.
Sander et al. concluded that although the UIIP was twice as expensive as a
targeted-population program, influenza cases were reduced by 62% and influenzaassociated mortality fell 28%. The reduction in hospital visits and end-of-life care are
largely responsible for an overall reduction in influenza treatment service costs by 52%.
Unfortunately, the researchers indicated that the study design does not effectively prove
causality between the findings and the UIIP. It should be noted that this research did not
conclude that the program was cost-effective.
According to the research, the UIIP cost $40 million Canadian dollars (CAD) to
run as opposed to the $20 million CAD cost of a targeted program. The $20 million CAD
increase was partially offset by a $7.8 million CAD decrease in healthcare costs –
resulting in a $12.2 million CAD cost of running the UIIP program – a cost the research
still called “economically attractive” (Sander, 2010 p.6). This analysis did not account for
indirect costs of influenza. There was no calculation of lost productivity – only direct
medical costs were included. If an indirect variable had been included, the results might
have shown an increase in QALYs and a reduction in economic cost.
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1.6. Vaccination Trends and Goals
Healthy Vermonters 2020 is Vermont’s health assessment plan. This most recent
iteration of Healthy Vermonters represents the third decade of the program, in which the
Vermont Department of Health has set various health assessment goals that will ideally
be met by 2020. Any of the indicators included in Healthy Vermonters 2020 is taken
from the national initiative, Healthy People 2020. Healthy People 2020 was created with
the objective of leveraging technological advancements and federal-state partnerships to
increase the life expectancy of Americans. The program identifies vaccines as being
“among the most cost-effective clinical preventative services” that can be provided to a
community (ODPHP, 2018). One of the selected objectives of Healthy People 2020 is to
“increase the percentage of noninstitutionalized adults aged 18 to 64 years who are
vaccinated annually against seasonal influenza.” The goal set forth by the program is to
have 80% of the target population immunized by 2020.
Coinciding with Health People 2020 is Act 191 – a section of the Vermont statute
written in 2006 that created the Vermont Vaccine Purchasing Program (VVPP). The act
states that the Vermont Department of Health (VDH) will administer an immunization
program ensuring “universal access to vaccines for all Vermonters at no charge to the
individual and reducing the cost at which the State may purchase vaccines” (18 V.S.A.
§1130, (b)(1)). The law continues to describe how the program will be organized and the
data collected by the Vermont Department of Health. Vaccines included in the VVPP are
to be purchased by the State from the CDC at the lowest possible cost. VDH is required
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to provide for the administration of the program, and insurers must remit the cost of both
dosage and administration in the form of a per-member-per-month assessment calculated
by an external vendor (18 V.S.A. §1130). This law is specific to Vermont, but similar
statutes exist across the country. The VVPP is the most likely means of executing a
universal vaccination program and is the basis of the usage of CDC contract dosage
prices used in the methods section of this research. The VVPP, however, can only
provide vaccines free of charge to primary care providers. Other administers of the flu
vaccine such as pharmacies, employers, schools, and retail stores must purchase the
vaccine themselves. Nevertheless, the VVPP is a potentially highly useful mechanism
for helping the state approach the influenza immunization goals laid out in both Healthy
Vermonters 2020 and Healthy People 2020.
Vermonters have their influenza vaccines administered in a variety of settings.
Traditional care settings such as hospitals and clinics have yielded considerable volume
to pharmacies, retail stores, and workplaces. Vermont’s Behavioral Risk Factor
Surveillance System (BRFSS) includes influenza vaccination questions in its annual
survey. Each year, the survey asks respondents if they have received an influenza
vaccination in the last twelve months. Unfortunately, the survey only asked respondents
to indicate the location they received the vaccination in three years: 2011, 2012, and
2015. About 4,000 individuals responded to this question each year; a little under half of
them indicated receiving a vaccination at all.
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Table 1: Vermont Vaccination Locations by Year

Vaccination Location
Doctor's Office
Work
Store
Hospital
Clinic
Other
School
VDH
Community Center
ER
Unvaccinated

2011
17.27%
10.66%
3.09%
3.74%
3.46%
1.04%
1.02%
0.41%
0.28%
0.02%
59.01%

2012
15.39%
9.53%
4.03%
3.80%
3.01%
1.17%
0.31%
0.20%
0.13%
0.00%
62.44%

2015 Weighted Average
15.22%
16.03%
11.12%
10.45%
7.28%
4.72%
2.34%
3.31%
2.12%
2.89%
1.15%
1.11%
0.72%
0.70%
0.40%
0.34%
0.12%
0.18%
0.07%
0.03%
59.44%
60.22%

Note. 4,626 responded to this question in 2011; 3,924 in 2012; and 4,009 in 2015.

Table 1 includes data taken directly from BRFFS data from the years 2011-2016.
It includes only years in which the point-of-service question was asked. Data is for
individuals who indicated they were between 18 and 64 years-old. The survey responses
were evaluated in SPSS using simple cross-tabulation. The data suggests a migration of
flu shot administration away from doctor’s offices and into stores. Unfortunately, the
definition of “store” is left up to the respondent, but it likely includes stores with
pharmacies, such as convenience stores and supermarkets. Over all the years included in
the data, women (50.3%, n=21,223) were more likely to be vaccinated than men (44.3%,
n=15,732) and respondents with an annual household income over $75,000 (51.6%,
n=18,111) were more likely to be vaccinated than respondents with an annual household
income under $75,000 (45.2%, n=7,555). More information on the BRFSS survey itself is
included in the next section.
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1.7. Data Sources
This research relies heavily on data from the State of Vermont and the Centers for
Disease Control and Prevention. Medical claims data comes from the Vermont
Healthcare Claims Uniform Reporting and Evaluation System (VHCURES). The
authority to collect and maintain medical claims information for state residents was
initially given to the Department of Financial Regulation. In 2013 that authority was
transferred to the Green Mountain Care Board (GMCB). The law states, “The Board shall
establish and maintain a unified health care database…” which includes patient and
provider identifiers, a uniform coding system, and information on all health care costs,
utilization, and enrollment information (18 V.S.A. §9410, (a)(1)). All health insurers,
“third-party administrators (TPAs), pharmacy benefit managers (PBMs), hospitals and
health systems, administrators of self-insured or publicly insured health benefits plans,
and any other similar entity with claims data, eligibility data, providers files and other
information relating to health care provided to Vermont residents” are required to provide
electronic claims data to the GMCB, which is responsible for collecting, storing, and
distributing data and statistical reports to interested and approved parties (GMCB, 2018).
Individual Vermont residents are permitted to opt-out of data sharing, and all external
reporting of the data must align with HIPAA regulations. The act also states that the
GMCB must collaborate with the Vermont Agency of Human Services, which is how the
data was made available for this research. It is a complete, comprehensive, and nearuniversal data set with extraordinary potential for health care research.
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Data from Vermont’s Behavioral Risk Factor Surveillance System (BRFSS) is
collected to better understand personal health behaviors of Vermonters. Although it is
not used in the economic or epidemiological modeling, BRFSS data helps provide
context to the issues addressed in this research. The surveillance system is a telephone
survey of randomly selected Vermont adults. The survey interviews between 6,000 and
7,000 residents each year, reaching out to residents through both land and cellphone lines
– there is potential for a self-selection bias. Each of the 50 states and the District of
Columbia have a BRFSS. Questions are typically about issues that are of interest to
public health: chronic disease prevalence, access, risk behaviors, and demographical
information is collected. Immunization information is collected as a means of assessing
the preventive behaviors of Vermonters; however, the questions asked in each survey are
not always consistent. The BRFSS helps inform many of the metrics for the Healthy
Vermonters 2020 and Healthy People 2020 indicators, and plays a role in supporting the
immunization registry, which provided key variables for epidemiological modeling.
Much of data in this model comes from the Centers for Disease Control and
Prevention, which is itself compiled from various surveys and studies conducted across
the country. FluVaxView data (used to generate vaccination rates in the epidemiological
modeling) comes from the National Immunization Survey–Flu, the National Health
Interview Survey, the BRFSS, and the Pregnancy Risk Assessment Monitoring System.
State and national surveys report their data to the CDC, which compiles, organizes, and
analyzes it. FluVaxView data is presented in a web-based dashboard where it can be used
by the public. The categorization of information, however, is not the same from year to
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year. Vermonters 18 to 64 years old were not grouped together for each year of
FluVaxView’s existence. The years the data was available (2010 onward) provided a
boundary for this study, as metrics for a larger time frame were not easily available. It
should be noted here that at the time this research was conducted, VHCURES claims data
was only available from 2010 – 2015 – thus limiting this project to five years.
CDC data was used for two other key variables in the cost-benefit model:
estimating the vaccine effectiveness in a given flu season, and estimating the medically
attended influenza rate. The vaccine effectiveness is gauged through CDC-conducted
studies that attempt to measure the additional benefit of a seasonal flu vaccine. The CDC
works with various universities and hospitals to conduct observational studies using
“medically attended laboratory-confirmed flu” as the outcome; the group of researchers is
called the “U.S. Flu Vaccine Effectiveness (VE) Network” (CDC, 2018). Five study sites
measure VE using a highly effective rRT-PCR lab test to test for the influenza virus.
Each of the studies compares the odds of being vaccinated prior to the medical visit for
all confirmed cases of influenza. The results are then adjusted for various location and
biological demographics.
CDC data estimating averted illnesses were interpolated to estimate the percent of
influenza illnesses that were medically attended for each of the study years. Annually, the
CDC uses vaccine effectiveness, vaccine coverage, and influenza hospitalization rates to
estimate averted illness, medical visits, and deaths by age cohort. This research compares
the sum of the averted medical visits and deaths to the total estimated averted illness to
arrive at an estimated percent of medically attended influenza by year. Data is for all
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adults age 18-64 across the entire U.S. and is assumed to be representative of Vermont’s
populations. The CDC warns that since the data is based on telephone survey responses,
recall bias, self-selection bias, and low response rates are limitations (CDC, 2018).
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CHAPTER 2: METHODS
This study uses cost-benefit analysis centered around a compartmental dynamic
transmission model. It takes a historical perspective, beginning with the five historic flu
seasons between 2011 and 2015, and asks the question, “What savings or additional costs
would have been incurred over the five flue seasons between 2010 and 2015 if the
vaccination was made free and available to all Vermonters?”
The cost analysis compares the per-capita annual economic impact of influenza in
Vermont before and after two interventions: the inclusion of influenza in the Vermont
Vaccine Purchasing Program and a 10 percent increase in vaccination rates.
Because this research takes the historical perspective, many of the cost variables
are known or can be derived from claims data. In some cases, prior studies were utilized.
The epidemiological variables, however, were not readily available. A susceptibleinfected-resistant (or SIR) model was used to estimate rates of illness during the study
period, as well as to incorporate the effects of herd immunity into the cost-analysis.

2.1. Susceptible-Infected-Resistant (SIR) Modeling
There are two different categories of models that can be used to evaluate disease
transmissions – static and dynamic. Static models are simpler (and often based around
linear equations) but they fail to capture the herd effect that is often a key component in
infectious disease modeling. Although pseudodynamic approaches have attempted to
capture herd effects without introducing derivatives, a true dynamic model is best suited
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to capture the economic factors associated with influenza vaccination programs (Van
Vlaenderen, 2013).
The SIR model, depicted in Figure 1, is a rudimentary dynamic transmission
model often used in epidemiology. This compartmental model classifies the population
into three categories: susceptible, infected, and resistant. Because influenza is a
communicable disease, static economic models often fall short of capturing the
epidemiological components. An individual’s probability of infection at any point in
time is a factor of the number of infected individuals in the population, and both variables
change over an influenza season (Pitman, 2012).

Figure 1: SIR model diagram

The model works by moving individuals between three categories. Susceptible
individuals are individuals who are not sick and not resistant, and therefore at risk of
infection. Infected individuals are people who have the influenza virus and are
contagious. Resistant individuals (sometimes called “recovered”) are individuals who are
not at risk of infection. This study uses “resistant” because it is possible to become

33

resistant through vaccination in addition to recovering from illness. The relationship is
best represented in a series of differential equations:
=
=

− ∗

∗

∗

∗

=

−

∗

∗

Here, β is the coefficient of transmission, the rate at which infected individuals
transmit the disease to susceptible individuals; γ is the coefficient of natural retirement,
the length of time (modeled here in weeks) in which an individual is most contagious; n
is the population; and S, I, and R are the percent of the population that are susceptible,
infected, and resistant at any point in time t. Here, t is a representation of weeks. Both β
and

are derived from literature.

is taken fromfrom Pradas-Velasco (2008), and β is

calculated from an R0 of 1.3 (Coburn, 2009) using the following equation from PradasVelasco:
β=

∗

is the reproductive rate of the virus represented as the average amount of
susceptible infected for every sick individual – this figure can be found in the literature.
As mentioned above, vaccination increases the pool of resistant individuals
without having them first become infected. It complicates the model slightly:
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where individuals are moved directly from the susceptible category to the resistant
category at a rate of v, which is calculated as the “effective coverage” of a vaccination, or
the percentage of the population vaccinated multiplied by the vaccine effectiveness. As
either of those factors increases, so does v, and more individuals are moved from the
susceptible group to the resistant group, leaving a reduced portion of the population to
become infected and therefore infect others.
It should be noted that the above equation provides a theoretical framework which
has been applied to this project using discrete time modeling, with one-week intervals.
The actual equations used in the discrete time SIR model are as follows.
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Table 2: SIR model variables

Year
2011
2012
2013
2014
2015

n
1.000
1.000
1.000
1.000
1.000

β
0.557
0.557
0.557
0.557
0.557

γ
0.429
0.429
0.429
0.429
0.429

Ro
1.3
1.3
1.3
1.3
1.3

V
0.389
0.365
0.411
0.421
0.412

VE
0.60
0.47
0.49
0.52
0.19

v
0.233
0.172
0.201
0.219
0.078

Population
Infected Annually
0.065
0.096
0.084
0.074
0.190

Note. The portion of the population identified as susceptible, infected, or resistant at any point in time is
represented as a percentage.
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Table 2 shows the SIR variables used for each year of the study. In the case of this
model, , and R0 were taken from literature (Pradas-Velasco, 2008 and Coburn, 2009
respectively) and β was calculated using the equation provided above. Determining the
R0 for seasonal influenza can be very difficult: there is no good record of how many
individuals in a year contract the virus, and disease resistance in individuals can carry
forward from previous years – this research used an R0 of 1.3 for each of the historic
years, which was identified as the mean for seasonal strains of influenza (Coburn, 2009;
Biggerstaff, 2014). The coefficient of natural retirement, , can also be found in the
literature: Chowell et al. in 2008 determined it to be 4.1 days; n the same year PradasVelasco et al. used 3.5 days, deviating from previous research (which indicated a natural
retirement coefficient of 3 days) to have their model better fit empirical data. This model
uses a

of 3 days (expressed here as .429 weeks) to fit the model to the generally

accepted prevalence of influenza – between 5 and 20 percent, depending on the year
(Biggerstaff, 2014). A

of .429 results in a β of .557 once it is multiplied by R0.

After β, , and R0 were used to form the basis of the SRI model, weekly effective
vaccination coverage (EC) was calculated using historic vaccination (V) and vaccine
effectiveness (VE) rates. Historic Vermont vaccination rates were taken directly from the
CDC immunization registry data for ages 18 to 64. Medical claims data was queried to
find the distribution of vaccines in each of the study years. The claims data was used to
distribute the historic vaccination rates across the influenza seasons – resulting in an
estimated percent of the population vaccinated each week. This number was multiplied
by seasonal VE to produce EC by week. The VE is then applied to the SIR model. The
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susceptible population in a given week was multiplied by the weekly effective coverage
to determine how many individuals are moved directly to the resistant population,
thereby skipping the infected category, and reducing both the individuals transmitting the
disease as well as the individuals to which the disease can be transmitted. Figure 2 shows
weekly vaccination estimates, derived from medical claims data and CDC reported
vaccination rates for adults 18-64.

% of Vermonters Vaccinated
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Figure 2: Vermont influenza vaccination trends by year

Discussions with Vermont’s state-run immunization program suggest that the first
cases of influenza typically begin the first week of December (the 23rd week of the
identified flu season), which this research reflects. The percent of the population
estimated to be initially infected was set at 0.175% for each year of the study. This figure
fits the model to the expected prevalence of influenza in a population, derived from the
literature.
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The results of the SIR model were then incorporated into the cost analysis model
to understand the frequency with which Vermonters became infected with influenza and
received medical treatment. The model also allows for the incorporation of a potentially
higher adoption rate due to increased access to the vaccination. By adjusting the V in the
SIR model, we can accommodate the benefits of the decreased risk of infection of
unvaccinated individuals that is isolated with the herd effect.

Herd Effect by Flu Season
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Figure 3: Herd Effect by Flu Season

Figure 3 shows the relationship between vaccination rate and infection rate for
each of the five study years. The Healthy Vermonters and Healthy People goal of an 80%
vaccination rate is depicted by a black vertical line. This graph brings to light several
complications of herd immunity. First, it is important to note that there are still
diminishing returns on the increase in vaccination rate. Each new dosage results a smaller
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reduction in the annual infected population than the last. The dynamic nature of herd
immunity, however, means that these returns diminish slower than if only the direct
effects of vaccination are considered.
Second, even with 100% vaccination coverage there are still sick individuals in
this model. This is because the graph above assumes same distribution of vaccinations
across the flu season as the data indicated. If all of these individuals were vaccinated in
the late fall, before the beginning of the flu season, the infection rate at 100% vaccination
coverage would be much closer to zero. It’s also important to consider the vaccination
effectiveness each year. The 2014-2015 season, for example, had a vaccination
effectiveness of only 19% - meaning that even with a fully vaccinated population, the
effective coverage would still only be 19%. This graph does take into account the initial
infection percentage by multiplying the aforementioned 0.175% by the change in size of
the resistant population at the onset of the epidemic.
Although a herd immunity threshold is an important concept to study and a good
goal for a public health system to try to achieve – it is largely dependent on factors
outside the control care providers: the vaccine effectiveness and the timeframe in which
the vaccines are administered.

2.2. Cost Analysis – Historic Variables
The cost analysis model compares the societal direct and indirect costs of
influenza vaccination and treatment before and after an intervention. All costs are
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represented per Vermonter aged 18 to 64, and the same methods are repeated for each of
the five study years. All costs are reported in 2017 U.S. dollars. The Bureau of Labor
Statistics’ CPI inflation calculator was used to bring all costs contemporary. All medical
costs are represented as “total reimbursed.” This figure ignores the amount charged by
the providers, and instead sums all payments made by insurers and individuals (in the
form of payments, copayments, prepayments, coinsurance, and deductibles).
At its most fundamental level, the model is:
∗

+
=
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is the historic vaccination rate;
is the historic treatment rate;

altered vaccination rate;
treatment rate; and
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is the historic vaccination cost;

is the historic treatment cost;

is the altered vaccination cost;

is the

is the altered

is the altered treatment cost. Table 3 gives an overview of

each model variable and its components. In this model, “treatment cost” refers to all
direct and indirect costs affiliated with influenza illness, including work absenteeism.

Table 3: List of Cost Model Variables

Variable

Component

Calculation
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Source

VRate

VCost

VCost

VCost

VCost

TRate
TCost

TCost

TCost

TCost

Vaccination
Rate

Taken directly from the
US CDC, 2017
Vermont vaccination
registry
Dosage
0: an average of all
VCHURES Claims
dosage lines from
Data; CDC
Vermont claims data
Vaccination
1: CDC pricing data and
Pricing; BRFSS
VT claims data weighted
Survey
by BRFSS survey data
Clinician
Taken from Claims Data VHCURES Claims
CPT Code 90471
Data for each
“Immunization
individual year and
administration for
inflated to 2017
Vaccines/Toxoids”
USD
Productivity
Lost productivity of
Buxton Bridges,
patient due to
2000;
vaccination. ½ hour
Vermont
multiplied by average VT
Department of
wage each year.
Labor - inflated
Program
Only in intervention – 1: KidsVax Contract
Administration
the added cost of
administering the
Vaccination program
Treatment Rate
SIR Dynamic
Paradas-Velasco,
Transmission Model
2008
Medical Care
Claims data for
VHCURES Claims
commercially insured 18Data,
64-year-olds. Multiplied
US CDC, 2017
by medically attended %
of infected
Medicine
Over the counter
Molinari, 2007
medicines, adjusted to
2017 USD
Productivity
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Historical vaccination costs were queried from the Vermont Health Care Uniform
Reporting and Evaluation System (VHCURES) medical claims data. Service dates were
grouped into flu seasons, each beginning on the first of July and ending on June 30 the
following year. The claims data were then reduced to show only payments made on
claims lines with an influenza vaccination, identified by the following Current Procedural
Terminology (CPT) codes: 90630, 90674, 90682, 90685, 90686, 90687, 90688, 90749,
90756, 90656, 90658, and 90673. Each of these codes represents a different vaccine
administered. The claims were further reduced to include only claims paid by commercial
insurers, and exclude patients over the age of 65 or under the age of 18, individuals
residing out of state, and claims that were denied by the insurer.
The average cost (across all payers) was calculated by vaccine type (determined
by CPT code) and weighted by the frequency with which the vaccines were administered
to estimate the average total reimbursed costs of all vaccines across all payers. Of the 12
CPT codes originally queried, only four were used throughout the course of this study.
These four vaccination types accounted for 99.98% of all influenza vaccines
administered, and VHCURES data and the Green Mountain Care Board disallow the
reporting on such small samples to protect patient confidentiality. The weighted cost by
flu season is used in the economic model.
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Table 4: Vermont Vaccine Costs and Weights by Flu Season
Vaccine
Afluria (IIV3) multi-dose vial
Fluzone (IIV4) single-dose vial
Afluria (IIV3) single-dose syringe
Afluria (IIV4) multi-dose vial
Weighted Average

CPT
90658
90686
90656
90688

2010-2011
Cost
%
$ 17.15 0.742
$ 0.000
$ 24.82 0.258
$ 0.000
$ 19.13 1.000

2011-2012
Cost
%
$16.55 0.729
$ 0.000
$20.89 0.271
$ 0.000
$17.73 1.000

2012-2013
Cost
%
$17.66 0.655
$ 0.000
$20.07 0.345
$ 0.000
$18.49 1.000

2013-2014
Cost
%
$17.30 0.563
$20.50 0.011
$18.69 0.414
$16.73 0.011
$17.91 1.000

2014-2015
Cost
%
$ 15.17 0.393
$ 29.62 0.291
$ 18.12 0.250
$ 18.56 0.066
$ 20.34 1.000

Note. n=199,559 across all five years of the study period. The sample sizes for flu season 2010-2011
through 2014-2015 were 40,017, 39,534, 42,056, 40,037, and 37,915 respectively. All costs are
representations of total reimbursed and are in 2017 U.S. dollars. “%” column represents the percent each
vaccination was administered compared to all influenza vaccinations in the corresponding year.

Clinician costs associated with vaccine administration were also taken directly
from the claims data. CPT code 90471 is used specifically for a single injection of a
vaccine. It should be noted that this figure was considerably higher than the cost
produced by Bridges et al. in 2000, who multiplied an estimate of the administering
clinician’s salary by 0.25 hours.
Finally, this model includes a measure of productivity lost by the vaccine
recipient. Bridges et al. estimated the time lost to be 30 minutes. This research multiplies
the average Vermont wage in each study year by .5 hours to estimate the total cost of lost
productivity.
The costs were then summed and multiplied by each year’s vaccination rate (V),
which is taken directly from the CDC’s immunization registry, which reports the number
specifically for 18-64-year-olds. This produced the cost per Vermonter for influenza
vaccination that is used in the model. The Vermont Vaccine Purchasing Program supplies
vaccines only to primary care providers. Because of this, not all administers of the
vaccine received the reduced dosage price that the CDC provides to government
purchasers. The dosage component of the vaccine cost in the intervention side of the
model (VCost1) was weighted using BRFSS survey data. Because the survey only
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included a question about vaccination provider in three of the five study years, linear
estimates were used for the remaining two years (2012-2013 and 2013-2014). Individuals
who received their vaccination from clinics, hospitals, or doctor’s office were considered
to have been vaccinated by a primary care provider and received the reduced rate in the
intervention.
The cost of treatment (TCost) was calculated using similar methods, but the
equation included more variables, including the imbedded SIR model. Medical costs
were queried from VHCURES medical claims data. The query divided the data into the
same flu seasons used to determine vaccination costs, then identifieed claims with an
influenza-specific International Statistic Classification of Diseases and Related Health
Problems (ICD) code. These codes differ from the CPT codes used in that they identify
diagnoses (influenza), rather than procedures (vaccination). Because many cases of
influenza go undiagnosed, these costs can only be applied to the percent of infected
individuals who are medically attended, which is extrapolated from CDC data. Other
research has used codes for influenza, influenza-like illness, and upper respiratory
infection, but this research uses only influenza ICD codes: 487, 4870, 4871 and 4878.
Every medical claim with any indication of an influenza diagnosis was identified. Again
the list was then reduced to include only claims paid by commercial insurers and exclude
patients over the age of 65 or under the age of 18, individuals residing out of state, and
claims that were denied by the insurer – the same criteria used to identify vaccination
claims. Once the claims had been identified, the total reimbursed for all claim lines was
summed to capture the medical treatment cost of influenza. This insured that all
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procedures associated with the influenza diagnosis were included in the total medical
costs.
Not all influenza cases are treated by medical personnel. In fact, most influenza
cases do not have a clinician encounter at all. To capture the medical costs per
Vermonter, it was necessary to estimate the percentage of influenza cases that were
medically attended. This figure is calculated from CDC data. The CDC estimates medical
visits and total influenza cases each year – the ratio of these two figures is the percent
medically attended. Unfortunately, there is no state-specific data on influenza.
The cost of over-the-counter medications has previously been estimated at $3 per
patient (Molinari, 2007). This figure was adjusted for inflation and included in the
treatment cost variable. Lost productivity due to influenza has been assumed to be two
days. Vermont Department of Labor wage data was used to estimate the average wage
loss. Pharmaceuticals (typically to mitigate pre-existing conditions exacerbated by
infection) were estimated at $49.38 per medical patient in the literature (Bridges, 2000),
and adjusted to $72.98 2017 U.S. dollars. This too was multiplied by the percent of
medically attended.
All treatment costs were then summed and multiplied by the percent of the
population infected by year, which is generated by the SIR model. This produced the
average treatment costs for commercially-insured 18-64-year-old Vermonters. The
average treatment costs were added to the average vaccination costs to produce the
average cost of influenza per commercially insured 18-64-year-old Vermonter.
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Table 5: Cost analysis variables by year for Vermont

VCost

VRate
TCost

TRate

VCost

VRate
TCost

TRate

Variable
Historic
Dosage (Historic Price)
Clinician
Productivity
Administration
Vaccination Rate
Medical Care
Pharmaceuticals
Medically Attended Influenza
Medicine
Productivity
SIR Infected %
Intervention
Dosage (Historic Price)
Dosage (VVPP Price)
PCP Administerd Vaccienes
Weighted Dosage Price
Clinician
Productivity
Administration
Vaccination Rate
Medical Care
Pharmaceuticals
Medically Attended Influenza
Medicine
Productivity
SIR Infected %

2010-2011 2011-2012 2012-2013 2013-2014 2014-2015
$ 19.13 $ 17.73 $
$ 24.34 $ 23.84 $
$ 11.39 $ 11.24 $
$
$
$
0.389
0.365
$ 345.84 $ 401.35 $
$ 72.98 $ 72.98 $
41.3%
40.8%
$ 4.01 $ 4.01 $
$ 364.50 $ 359.52 $
6.5%
9.6%

$ 19.13 $
$ 9.29 $
62.9%
$ 12.94 $
$ 24.34 $
$ 11.39 $
$ 0.34 $
42.8%
$ 345.84 $
$ 72.98 $
41.3%
$ 4.01 $
$ 364.50 $
5.7%

Note. 2017 US dollars.
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17.73
11.95
60.8%
14.22
23.84
11.24
0.44
40.2%
401.35
72.98
40.8%
4.01
359.52
8.6%

18.49
25.91
11.12
0.411
566.15
72.98
40.9%
4.01
355.82
8.4%

$ 17.91 $ 20.34
$ 27.73 $ 29.58
$ 11.13 $ 11.52
$
$ 0.421
0.412
$ 739.78 $ 513.42
$ 72.98 $ 72.98
38.8%
41.3%
$ 4.01 $ 4.01
$ 356.26 $ 368.58
7.4%
19.0%

$ 18.49 $
$ 11.75 $
52.0%
$ 14.99 $
$ 25.91 $
$ 11.12 $
$ 0.43 $
45.2%
$ 566.15 $
$ 72.98 $
40.9%
$ 4.01 $
$ 355.82 $
7.4%

17.91
11.58
48.7%
14.82
27.73
11.13
0.43
46.3%
739.78
72.98
38.8%
4.01
356.26
6.5%

$ 20.34
$ 12.27
47.8%
$ 16.49
$ 29.58
$ 11.52
$ 0.45
45.3%
$ 513.42
$ 72.98
41.3%
$ 4.01
$ 368.58
17.9%

2.3. Cost analysis – Intervention Variables
The same methods are used in the intervention side of the cost analysis model
with very few changes in the values used. It’s important to note here that the creation of a
universal influenza vaccination program will likely entail different statutes, laws, and
regulations depending on the population served. In the case of Vermont, the means of
vaccination distribution is the Vermont Vaccine Purchasing Program (VVPP), which is
mandated by state statute to “purchase vaccines from the federal Centers for Disease
Control and Prevention at the lowest available cost.” (Act 191, 2006). This has
implications for Vermont’s implementation of such a program that might not be
experienced in other scenarios. It means that all dosage prices would be lowered to the
CDC’s cost per dose, which is represented in Table 5.

Table 6: CDC Cost per dose by year

Vaccine
Afluria (IIV3) multi-dose vial
Fluzone (IIV4) single-dose vial
Afluria (IIV3) single-dose syringe
Afluria (IIV4) multi-dose vial*

CPT
90658
90686
90656
90688

2014-2015
$ 6.53
$ 13.58
$ 7.29
$ 11.35

2013-2014
$ 7.82
$ 9.93
$ 8.13
$ 11.35

2012-2013
$ 8.25
$ 10.53
$ 9.00
$ 11.35

2011-2012
$ 8.25
$ 10.97
$ 9.00
$ 11.35

2010-2011
$ 8.25
$ 10.97
$ 9.00
$ 11.35

Table 6 shows the prices taken directly from CDC’s website. They reflect the
CDC contract price for each influenza vaccination in January of the respective flu season.
The vaccination costs were weighted according to the frequency with which each was
administered, and the weighted average cost was used as the dosage cost in the VCost
variable of the cost-analysis model. The weighted averages used can be found in Table 4
and range from $9.29 during the 2010-2011 flu season to $12.27 during the 2013-2014
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season. This resulted in a reduced cost-per vaccination. The lost productivity of the
patient and the cost of the clinician are assumed to be the same as in the historical data.
Another small difference is the cost of administering the VVPP program itself.
The current contract with KidsVax – the third party through which the VVPP is run –
calculates the administration cost as 2.7% of the dosage price. That expense varies year
to year, is included in Table 4, and is added to the VCost of the intervention portion of
the model.
The final variation between the historical and intervention variables comes from
anticipated increases in adoption rate, and the effects of this increase on the nonvaccinated population. The Vermont Department of Health’s immunization program
chief estimates a 10% increase in vaccination rates once the vaccines become available to
all Vermonters, free of charge. The SIR model is used to calculate the effects of this
increase in vaccination rates on the instances of influenza in the state of Vermont. In
each of the five study years, the vaccination rate provided by the CDC’s registry was
increased by 10%, with the additional vaccinations being distributed according to the
figures queried from the VHCURES claims data. The Vermont Department of Health’s
Immunization Chief believes 10% to be a conservative increase – it is conservative
compared to the increase associated with Rhode Island’s influenza vaccination program:
20.7% over four years.
This increase in vaccines administered reduces the infected population in two
ways. First, it increases the effective vaccination rate, moves more individuals from the
susceptible category to the resistant category – in SIR modeling, vaccinated individuals
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are moved from the susceptible to resistant category at a rate in line with the vaccine
effectiveness. They are resistant, and no longer susceptible to the disease, nor are they
infected and able to transmit it on to others. Second, because there are fewer infected
individuals in the infected category at any point in time, there are fewer instances of viral
transmission between the infected and susceptible individuals.
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CHAPTER 3: RESULTS
If the State of Vermont had included influenza in its Adult Vaccination
Purchasing Program for the five flu seasons between fall 2010 and summer 2015, the
total economic burden associated with influenza would have been reduced by 6.2%.
These societal savings are leveraged chiefly from two mechanisms. First is the drop in
dosage price associated with the inclusion of the vaccination in the VVPP. The average
cost to vaccinate a Vermonter falls by 12.31% when purchased directly from the CDC at
the CDC contract rate – this difference includes the additional cost of administration. By
holding the rate of vaccination (and the entire SIR mode) constant and changing only the
vaccination cost variable, the five-year average influenza-associated cost to Vermonters
falls by 1.7%.
The remaining savings are experienced through the assumed increase in
vaccination rate. Vermont immunization officials estimate this increase to be about 10%
due to increased supply of vaccines (there would be no charge to providers in the VVPP)
and the removal of economic barriers. Without including the indirect benefits of
vaccination (herd immunity) a ceteris paribus increase in vaccination rate does not yield
societal savings – the increase in the cost of vaccinating a society is not offset by
treatment savings because there is no decrease in chance in infection among the
unvaccinated. However, when the indirect effects are included, the additional reduction in
treatment costs render the program cost-effective. Accounting for only the change in
vaccination rate (and associated SIR model results) the five-year average cost of flu falls
by 4.3%.
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Table 7 depicts model inputs and results for each of the study years. The
historical variables are estimates of the actual influenza costs, per Vermonter, for each of
the study years. The intervention variables depict the altered cost in each of the years.
The individual results from each year are included, along with a weighted average for all
five study years. Each individual year was weighted by the population of Vermonters
aged 18-54. Influenza cost per Vermonter is a calculation of influenza costs to all
Vermonters, not just sick Vermonters – the dramatic increase during the 2014-2015
season is due to more Vermonters contracting the virus, and not due to the virus being
expensive to treat on a case-by-case basis.
Table 7: Simulated cost analysis results

Variable
Historic
Vaccination Rate
Vaccination Cost
Vaccination Cost Per Vermonter
Treatment Rate
Treatment Cost
Treatment Cost Per Vermonter
Influenza Cost Per Vermonter
Intervention
Vaccination Rate
Vaccination Cost
Vaccination Cost Per Vermonter
Treatment Rate
Treatment Cost
Treatment Cost Per Vermonter
Influenza Cost Per Vermonter
Savings Per Vermonter

Weighted
2010-2011 2011-2012 2012-2013 2013-2014 2014-2015 Average

$
$
$

36.5%
52.80
19.27
9.6%
556.88
53.57
72.84

42.8%
$ 49.01 $
$ 20.97 $
5.7%
$ 541.52 $
$ 30.89 $
$ 51.87 $
$ 4.89 $
8.6%

40.2%
49.73
19.97
8.6%
556.88
47.72
67.68
5.16
7.1%

$
$
$
$
$

38.9%
54.86
21.34
6.5%
541.52
35.42
56.76

$
$

$
$
$

42.1%
56.77
23.90
7.4%
675.75
49.74
73.63

45.2%
$ 52.46 $
$ 23.72 $
7.4%
$ 621.38 $
$ 45.98 $
$ 69.69 $
$ 5.07 $
6.8%

46.3%
54.11
25.06
6.5%
675.75
43.65
68.71
4.92
6.7%

$
$
$
$
$

41.1%
55.52
22.82
8.4%
621.38
51.95
74.77

$
$

$
$
$

39.9%
56.26
22.51
10.2%
601.74
61.35
83.86

45.3%
$ 58.04 $
$ 26.30 $
17.9%
$ 614.84 $
$ 110.20 $
$ 136.51 $
$ 5.87 $
4.1%

43.9%
52.64
23.18
9.2%
601.74
55.50
78.68
5.18
6.2%

$
$
$
$
$

41.2%
61.44
25.31
19.0%
614.84
117.06
142.38

$
$

Note. All Per Vermonter figures are representations of commercially insured 18-64-year-old Vermonters.

As expected, potential savings vary from year to year depending on several
factors. Chief among these is the effective coverage (EC) rate, calculated by multiplying
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the vaccination rate (V) by the vaccination effectiveness (VE). The 2010-2011 season, for
example, had a high EC of 23.3% (38.9% vaccination rate and 60% vaccine
effectiveness) and resulted in potential savings of 8.6%. On the other hand, the EC in
Vermont during the 2014-2015 flu season was only 7.8%. This is due to a largely
ineffective vaccine (VE = 19%) which offset a relatively high vaccination rate (V =
41.2%) and resulted in the lowest savings (4.1%) of all the study years.
Some of the most important findings resulting from this research are the dynamics
between the various variables in the model. Sensitivity analysis can help illustrate the
interdependence of variables, and how each of them relate to the cost-benefit of
vaccination. This sensitivity analysis was conducted by re-running the model with and
adjusting only one variable each time. By holding the rest of the model constant, we gain
a better understanding of the magnitude each component has on the resulting savings.
Table 8: Sensitivity Analysis

Variable Name
Variable
Results (% 5-year Savings)
SIR Variables
Coefficient of Transmission (+/- 5%)
β
0.529 0.557 0.585
25.5% 6.2% -21.8%
Coefficient of Recovery (+/- 5%)
γ
0.408 0.429 0.450
7.9% 6.2% 4.4%
Reproductive Rate (+/- 5%)
Ro
1.235 1.3 1.365
25.5% 6.2% -21.8%
Intervention Vaccination Increase (+/- 5%)
Vi
0.05 0.1 0.15
4.1% 6.2% 8.0%
Vaccine Effectiveness (+/- 5%)
VE
-5%
+5%
2.5% 6.2% 9.6%
Cost-Effectivenss Variables
Vaccination Cost (+/- 10%)
Cost -10%
+10%
6.4% 6.2% 5.9%
Treatment Cost (+/- 10%)
Cost -10%
+10%
5.9% 6.2% 6.4%
Note. The center figure for each variable was the number used in the final version of the model. The
number to the left and right represent variations to that variable, the corresponding savings can be found
under the results header of the table.

Table 8 shows sensitivity analysis for some of the variables included in the model.
The same coefficient of transmission, coefficient of recovery, reproductive rate, and
interventional vaccination increase were used in all study years; this analysis adjusted
52

that variable the same amount in each of those years. For variables which changed from
year to year (vaccine effectiveness, vaccination cost, and treatment cost) a percentage
change to the variable was applied. This model was not sensitive to changes in
vaccination cost and treatment cost – a 10% change had to be used in order to display a
difference in the resulting 5-year savings.
The variables with the most dramatic effect on the results were the coefficient of
transmission and the reproductive rate of the virus. These two variables are very related.
The coefficient of transmission represents the rate at which infected individuals pass the
virus on to susceptible individuals in the SIR model. It is calculated by multiplying the
reproductive rate by the coefficient of recovery. Even a slight increase in the
infectiousness of a disease has substantial effects on the cost-benefit of a vaccination. A
more contagious virus is harder to treat by vaccination in a population because the
unvaccinated individuals can infect a higher number of unvaccinated individuals – the
marginal benefits of each person vaccinated are diminished. There is little that can be
done by public health or medicine to alter either of these variables.
The coefficient of recovery has a similar but lesser effect on the cost-benefit of a
vaccination program. If the coefficient of transmission controls the flow from the
susceptible compartment to the infected compartment, the coefficient of recovery can be
thought of as determining the flow of the infected compartment to the recovered
compartment. The faster individuals move to the recovered compartment, the less time
they must spread the virus to the susceptible individuals. Perhaps counteractivity, a
higher coefficient of transmission, results in a reduced marginal benefit for additional
vaccinations. This is because the less time infected individuals must spread the virus, the
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lower the treatment cost is, per Vermonter – fewer people get sick. If the treatment cost is
lower relative to the vaccination cost, the cost of vaccination individuals is not as heavily
offset by the treatment savings. The CDC suggests that antiviral drugs can lessen the time
an individual is sick by one or two days – but also create additional costs and only affect
individuals who have been prescribed them and not the population as a whole.
Unsurprisingly, an increase in the uptake of vaccinations due to the
implementation of the program results in a more cost-effective program. If, for example,
vaccination rates increase 15% instead of 10% statewide, the 5-year average savings
would grow from 6.2% to 8.0%. Influenza vaccination programs should invest
considerably in educational campaigns and access-issue resolutions. The potential for
return on investment is appealing.
Vaccine effectiveness also increases the economic benefits of inoculation. When
vaccine effectiveness increases, so does the cost-benefit of the program. A more effective
vaccine increases the effective coverage rate, transitions more individuals directly from
susceptible to resistant, and enhances both the direct and indirect effects of vaccination.
Variation in the total cost of vaccination and treatment also affects the economic
outcomes of the model. What is interesting is that even relatively large variances in these
variables don’t alter the cost-benefit of the model to a large degree. Not surprisingly,
lowering the cost of a vaccine increases the effectiveness of the program. Lowering the
cost of the treatment does not.
The variables used in this model were either calculated from universal claims
data, taken from CDC or BLS databases, or derived from literature and chosen to fit
historical norms. Although the sensitivity analysis has shown that small variation in some
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variables can dramatically affect the outcome of the model, they also change the model
outcomes so that they no longer fit within the literature. From this research, a universal
influenza vaccination program could be cost-effective for the State of Vermont.
Additional savings would result from higher vaccination rates, which should be
encouraged through various means.
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CHAPTER 4: LIMITATIONS
Like all models, this cost-benefit analysis is not without its limitations. In all
instances an attempt was made to provide conservative estimates of the cost-saving
potential of a universal vaccination program.
Vaccine effectiveness varies by age and health status. As addressed earlier in this
paper, the vaccine effectiveness is lowest in the elderly and the highest in children and
young adults. The VE variables used in the model are averages for the entire population.
Because the model includes only working-aged adults, this might be an underestimate of
vaccine effectiveness – unfortunately, the CDC does not calculate VE for different age
cohorts. Similarly, the basic reproductive rate R0 varies between different age cohorts.
This is due to both physiological and sociological differences. As addressed earlier,
studies have shown the R0 of elderly populations to be lower than that of children and
young adults. This research uses an average of 1.3, but it might be an underestimate of
the reproductive rate in the study population. Both variables were kept at their societal
average to provide conservative estimates of potential savings.
In the literature, work absenteeism was calculated at anywhere from .5 to 3.8
days. This research uses 2 days to control for the confusion of “days ill” and work
absenteeism. If an individual is sick on the weekend, for example, there is no associated
lost productivity. It should be noted that there is no agreement as to what this variable
should be.
This paper uses a susceptible-infected-resistant (SIR) model to model the
transmission of infectious disease instead of a susceptible-exposed-infected-resistant
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(SEIR) model. The SEIR model includes an extra coefficient of time between exposure to
a pathogen and infection by that pathogen to account for the incubation period of the
virus. Future research could examine the impact of the inclusion of the incubation period
in the model.
Although claims data remains one of the most fully comprehensive sources for
health care information, it is now without its drawbacks. The VHCURES data is a
compilation of data from all providers and insurers in the state of Vermont uploaded and
unified in a database. The data is only as good as its sources, and the skill of those
compiling it. It can be unruly and sometimes inaccurate – typically the law of large
numbers reduces the impact of any irregularities, but in a state as small as Vermont the
impact of an error might be more significant. VHCURES data was made available
through the Green Mountain Care Board (GMCB). All query results, figures, and
analyses are from this research and not necessarily those of the GMCB.
Some variables in this model are based off survey data. Self-selection bias, and
recall bias are limitations in all self-reported survey data. Although not a limitation perse, special care is necessary when conducting an economic evaluation of a public health
topic. This research intentionally avoided socioeconomic classification of the population.
Because workplaces absenteeism is a measure of lost wages, the economics of
vaccination vary widely when the population is stratified by household income. All
health economic research must be careful to remain ethical when dealing with
socioeconomic class. It is for this reason that – aside from average VT wage – income
was not considered in the model, or when discussing selective vaccination programs. A
future iteration of this model, however, could look at the marginal value of wages lost.
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While it is true that quantifying work absenteeism of a high-earner results in a larger
economic loss to society in terms of GDP, it does not take into account the marginal
value of those earrings relative to the worker who earned them. Many wealth individuals
can easily (finically, at least) afford to be sick while lower wage-earners would struggle
to adjust for two days of lost earnings. Paid sick leave is a benefit that may not even be
available to the poorest of Vermonters or the self-employed. In order to better incorporate
health and economic equity into policy and public health decision, considerations must be
made to account for differences in earnings and socioeconomic status.
This research is a study of inter-pandemic, or seasonal influenza. It is a
retrospective study that reviews data from past flu seasons. The five years included in this
study are in line with expectations for seasonal flu infection rates. This study does in no
way accounts for flu pandemics, so called “black sawn” events, or other outliers. Flu
pandemics have historically been treated separately in the literature, and pose a rare but
severe risk to populations requiring different epidemiological analysis. Pandemic flu has
been excluded from this research.
Finally, this is largely a quantitative paper and therefore somewhat reductive in its
analysis. Economics, and in particular health economics must be mindful of the
importance of human nature. This paper does not account for the value of a life-year
added, or the willingness-to-pay for avoidance of influenza symptoms. Including such
variables would necessitate a much more comprehensive project, through their admission
must be noted as a limitation.
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CHAPTER 5: DISCUSSION
Seasonal influenza is an annual, global public health risk. Each year, tens of
thousands of people die from the infection and hundreds of thousands more are
hospitalized. While children and seniors are most at risk for serious complications, the
virus is indiscriminate, and can infect up to 26% of the entire population in a given year.
Although healthy adults do not see the same increase in influenza-associated
mortality as older and younger cohorts they can act as a vector, aiding the virus as it
moves among at-risk populations. Each season, influenza may be transferred from
children in child care and schools to the elderly via the parents and caretakers of the
youth. An intervention among 18-64-year-old adults not only reduces their risk of
infection, but that of the entire public.
Vaccination is a potent mechanism for this intervention, although the
effectiveness in any given year can vary. Depending on the year, vaccination can
decrease the chance of infection from anywhere between 10% to 60% (CDC, 2017).
Vaccination rates, too, vary dramatically by age, location, education, and socioeconomic
factors.
Despite these variations in both vaccine and population, evidence suggests that
vaccinating all persons over six months old is cost-effective. Insurers and patients would
certainly benefit from such a program. Insurers benefit because cost of the vaccine dose
included in the VVPP assessment would be less than the private-market price currently
available to providers and a higher vaccination rate means a reduction influenza-related59

illness claims; patients benefit because they will be able to receive the vaccination freeof-charge from primary care providers and will be less likely to become sick. It is unclear
if providers will benefit financially – although it will be easier for them to maintain an
adequate supply of vaccinations, revenue from flu vaccinations might outweigh the cost
to providers in the current system. More research is necessary to fully understand the
impact of an influenza vaccination program on providers.
Furthermore, the associated reduction in influenza-like illness hospitalizations and
mortality alleviates the strain on medical systems and frees up facilities and clinicians to
focus their attention elsewhere. Since 2010, the CDC’s Advisory Committee on
Immunization Practices has recommended all Americans six months and older receive an
annual flu vaccination. Simultaneously, national and state-level health assessment plans
have set target flu vaccination rates of 80% for adults.
Research conducted as part of this study has corroborated the literature and
recommendations from the CDC. The epidemiological cost-benefit model outlined in
this document has demonstrated that a more highly vaccinated population would have
resulted in considerable savings in Vermont’s health economy (all direct and indirect
economic activity affiliated with the health care system) over the five flu seasons
occurring between fall 2010 and summer 2015. A 10% increase in vaccination rates in
any of the evaluated years, with reductions in the cost of vaccines, would have resulted in
savings without any other intervention.
The Vermont Vaccine Purchasing Program (VVPP) – a state mandated program –
includes all CDC recommended vaccines for adults except influenza. The state statute
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requires that all vaccines included in the program be purchased at the lowest possible rate
and made available for order at no cost from Vermont primary care providers enrolled in
the program. Funding for vaccines is provided by health insurers.
If influenza vaccines were included in the VVPP, there would be two beneficial
effects for residents, insurers, and the population. First, the vaccines would be purchased
at a considerably lower cost, resulting in savings; and second, the reduction in cost would
increase access to the vaccine. Although access to care is itself a complicated issue,
suppliers of the vaccine would be able to keep a larger supply on hand without fear of
over-purchasing the product. At the same time, residents whose chief barrier to
vaccination was financial would now be able to receive a flu shot at no direct expense to
them. Because of these two factors, officials at Vermont’s Immunization Program
estimate flu vaccination rates could increase over 10%. At the recommendation of the
VVPP board, and the judgment of the Vermont Department of Health, influenza can be
included in the Adult Vaccine Purchasing Program and Vermont can make a large stride
towards achieving its public health goals.
There are several courses of action that can be taken with this information. The
first is to maintain the status quo and continue to allow market forces and homo
economicus to distribute vaccinations without intervention. There is little reason to expect
vaccination rates for working-aged adults to climb higher than 50% without some sort of
program and achieving the federal goal of 80% of the adult population vaccinated would
be unattainable.
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A second option is to expand awareness of the benefits of vaccination through
education, outreach, and marketing programs. Because vaccination is cost-effective,
funds contributed to this cause would benefit the public health of a population while
reducing the economic burden of seasonal influenza. As demonstrated in this research, a
10% increase in adoption rates among 18-to-64-year-olds is cost-effective even when all
other variables are held constant.
The third and most involved option would be to include influenza vaccinations in
the adult vaccination program. The VVPP would add influenza to the current suite of
vaccinations and provide them free of charge to Vermont primary care providers for use
in all patients. The added cost of the flu vaccine would be included in the per-member
per-month assessment charges to health care insurers and received by the State of
Vermont. This option has the most potential for savings. The reduction in dosage price
also serves to mitigate downside risk by reducing the financial burden of supplying the
vaccine to providers.
This research has uncovered other questions deserving of their own studies. It is
clear that when accounting for the indirect effect of vaccination (herd immunity),
economic and public health benefits associated with higher vaccination rates are
increased. This finding aligns nicely with the federal and local vaccination goals and begs
the question: how do we increase vaccination rates? Vermont’s public health officials
typically group their initiatives into three categories: public education; regulations and
policy; and health access. Each of these three approaches could increase vaccination
rates.
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As addressed above, a public education campaign could be created by the
Vermont Department of Health with the goal of informing the population of the personal
and societal benefits of vaccination. Historically, public educations campaigns have been
quite expensive and have not had much of an impact on vaccination rates. This could be
because of discounting rates and optimism bias. For many, it may be hard to part with the
up-front cost of vaccination because there is a chance of greater costs in the future. What
is not known is whether a lack of education about influenza vaccination is the reason for
the low adoption rates. Perhaps an incentive program paired with an education campaign
could increase vaccination rates. Such a campaign would likely have to be tailored to fit
the needs of each individual community. For example, some regions of Vermont might
need to be made aware of the public health benefits of vaccination while others would
need to be informed that it is being provided free-of-charge. Regardless, there is no
guarantee of the effectiveness of a marketing campaign in isolation. However, increasing
the public’s knowledge about vaccination is likely a necessary complementary
component to either a regulatory or access-increasing approach.
The second option – increasing vaccination rates through regulations and policy –
would certainly be cost-effective but potentially controversial. Vermont’s immunization
program management is well aware of the resistance to required vaccination. The
influenza vaccination does not have to be a population-wide initiative. The state could
introduce policy that would require only certain individuals to be vaccinated. Ideally this
would include adults who spend considerable time with high-risk populations and those
with a high likelihood of being a disease vector between various cohorts. Examples
63

include clinicians, child care providers, teachers, social workers, and those that work
closely with older populations.
The third method for increasing vaccination involves increasing access to flu
shots for Vermonters. Health care access issues take multiple forms, and Vermont must
consider all obstacles to best address the issue. The influenza vaccine may be inaccessible
due to transportation, economic, or social hindrances. Providing flu shot at no cost to
primary care providers addresses only one of these problems. Policies and public health
practices aimed towards increasing access will need to take multiple access issues into
account. Perhaps a mobile vaccination unit – similar to a mobile blood-drive or mobile
needle exchange operation – could be developed in order to provide vaccines to
Vermont’s rural regions. The Health Department’s district offices could also be called
upon to assess the need and plan for the distribution of vaccines across the state. Primary
care offices could be financially incentivized to increase their distribution of vaccines by
opening free clinics. Future research should survey the unvaccinated population to learn
the reasons individuals are not annually vaccinated and develop policy to address those
issues.
What is also apparent from this research is that there is a way to reduce the
societal and economic cost of seasonal influenza without increasing the vaccination rate
at all. The SIR model suggests that there is an optimal time for vaccinating against the
flu. This time is likely between October and December. It is evident from the claims data
that a healthy large portion of the population receives flu shots after the flu season is
already in full swing. This second wave of vaccinations typically happens in January and
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could be caused by a shortage in vaccination supply, or as a reaction to widespread
infection. Evidence suggests that if individuals who are vaccinated after January 1 were
instead vaccinated in the late fall/early winter, the susceptible population would be
reduced at an earlier date with no increase to the infected population. Because the flu
vaccination takes upwards of two weeks to be effective, many of those receiving the shot
late in the flu season do so futilely. Future research could work to identify the optimal
months for receiving a vaccination, determine the reasons why individuals receive their
shots late in the season, and develop a plan to better align the vaccination of the
population with the biologically optimal timeframe. This model is used in this research to
test a specific intervention for reducing the economic burden of influenza in the State of
Vermont. The model can be adapted for use in many other scenarios that require societal
economic modeling of transmittable diseases.
A 10% increase in Vermont’s influenza vaccination rate over the five flu seasons
between 2010 and 2015 would have created notable economic savings and freed up
health care resources across the state. The vaccination rates of the years studied were
aligned with rates Vermont typically experiences, and the prevalence of annual infections
included in the model mirrored data from the literature, each of which help to validate the
findings. Adding influenza to Vermont’s Adult Vaccine Purchasing Program would result
in further savings due to the reduction in dosage prices. Inclusion of influenza in the
VVPP would likely result in a healthier population at a reduced cost.
This paper is intended to be both a community development and applied
economics thesis. While the application of economic principles is apparent throughout, it
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is important to address the impact of immunization on communities. Public health can be
viewed as a public good: individuals acting in their own perceived self-interest can
detract from that public good, while emergent benefits (such as herd immunity) can arise
from a unified public health endeavor. Achieving optimal health through various policy
and regulatory methods is a task that often falls to community and government officials.
A healthy population is necessary to keep local networks, relationships, and economies
strong, healthy, and efficient. Promoting health improves communities, and
immunization against infectious diseases is a proven method of health promotion.
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